Mulon Luo is a counsel in the firm’s Technology Companies & Life Sciences group. Ms. Luo represents private and public companies in a range of industries including biotechnology, medical devices, diagnostics, healthcare information technology, Internet, and software. She regularly counsels clients on start-up and formation matters, venture capital financings, mergers and acquisitions, public offerings, SEC reporting and compliance, and other corporate, strategic, and corporate finance matters. She also has experience advising clients in the life sciences sector on technology transactions and commercial contract matters. She joined Goodwin in 2008, and has had the unique opportunity to have practiced in the firm’s Boston, New York and Washington D.C. offices.





Some of Ms. Luo’s representative matters include:

  • 5AM Ventures in its investment in a computational genomics company focused on identifying inherited disease risk in future generations and in a digital therapeutics company for enhanced clinical outcomes
  • A healthcare venture firm in multiple rounds of investment in an oral healthcare company that develops, acquires and commercializes oral health care technologies
  • Action Pharma, a privately owned Danish biotech company, in its $110 million sale to Abbott Laboratories
  • Axcella Health, a biotechnology company pioneering first-in-class medicines for serious conditions linked to amino acid imbalances, in multiple financing rounds, including its $42.5 million Series D financing
  • Endeca Technologies, a provider of unstructured data management, web commerce and business intelligence solutions, in its sale to Oracle
  • ExtendMedia, a provider of software-based content management systems, in its sale to Cisco
  • Lycera Corp. in its collaboration and buyout option transaction with Celgene Corporation with a value of up to $105 million
  • Moderna Therapeutics, a biotechnology company that researches and develops protein therapies based on mRNA technology, in multiple financing rounds, including its $110 million Series D financing and $500 million Series E financing
  • Ra Pharmaceuticals, a clinical stage biopharma developing a treatment for PNH, a rare orphan disease, in its $8 million Series A financing and $58.5 million Series B financing
  • The underwriters in the $50.9 million initial public offering, and subsequent follow-on offering, of a specialty pharmaceutical company focusing on the development and commercialization of products for treating central nervous system disorders
  • The underwriters in the $58 million follow-on offering of an international pharmaceutical company focusing on the development and commercialization of ancillary hemodialysis products

In The News









J.D., 2008
Boston University School of Law

(cum laude)

B.A., 2003
Yale University



New York
District of Columbia
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique